AVN 63.60 Increased By ▲ 1.85 (3%)
BOP 8.65 Decreased By ▼ -0.08 (-0.92%)
CHCC 124.50 Decreased By ▼ -2.00 (-1.58%)
DCL 8.85 Decreased By ▼ -0.06 (-0.67%)
DGKC 101.70 Decreased By ▼ -0.56 (-0.55%)
EFERT 61.65 Decreased By ▼ -4.90 (-7.36%)
EPCL 42.99 Decreased By ▼ -0.26 (-0.6%)
FCCL 20.40 Decreased By ▼ -0.05 (-0.24%)
FFL 13.67 Increased By ▲ 0.08 (0.59%)
HASCOL 13.39 Decreased By ▼ -0.08 (-0.59%)
HBL 128.88 Increased By ▲ 0.38 (0.3%)
HUBC 79.40 Increased By ▲ 0.54 (0.68%)
HUMNL 7.10 Increased By ▲ 0.72 (11.28%)
JSCL 21.85 Increased By ▲ 0.02 (0.09%)
KAPCO 27.60 Increased By ▲ 0.11 (0.4%)
KEL 3.60 No Change ▼ 0.00 (0%)
LOTCHEM 11.75 Decreased By ▼ -0.03 (-0.25%)
MLCF 36.51 Decreased By ▼ -0.74 (-1.99%)
OGDC 93.80 Increased By ▲ 1.44 (1.56%)
PAEL 30.35 Decreased By ▼ -0.10 (-0.33%)
PIBTL 11.78 Decreased By ▼ -0.01 (-0.08%)
PIOC 83.35 Decreased By ▼ -1.50 (-1.77%)
POWER 9.20 Increased By ▲ 0.05 (0.55%)
PPL 84.45 Increased By ▲ 1.91 (2.31%)
PSO 187.55 Increased By ▲ 1.06 (0.57%)
SNGP 43.00 Increased By ▲ 0.50 (1.18%)
STPL 13.30 No Change ▼ 0.00 (0%)
TRG 51.33 Increased By ▲ 0.23 (0.45%)
UNITY 23.34 Increased By ▲ 0.04 (0.17%)
WTL 0.99 No Change ▼ 0.00 (0%)
BR100 4,131 Increased By ▲ 19.61 (0.48%)
BR30 20,689 Increased By ▲ 66.76 (0.32%)
KSE100 39,863 Increased By ▲ 230.84 (0.58%)
KSE30 16,752 Increased By ▲ 58.2 (0.35%)
Business

EU regulator starts real-time review of Moderna's COVID-19 vaccine candidate

  • The European Medicines Agency's human medicines committee has started a "rolling review" of Moderna's mRNA-1273 vaccine candidate and is evaluating the first batch of data.
  • EMA's announcement comes a week after Switzerland began a real-time review of data from Moderna's vaccine candidate.
16 Nov 2020

Europe's health regulator said on Monday it had launched a real-time review of US drugmaker Moderna Inc's experimental COVID-19 vaccine, following similar such reviews of rival vaccines from AstraZeneca and Pfizer.

The European Medicines Agency's human medicines committee has started a "rolling review" of Moderna's mRNA-1273 vaccine candidate and is evaluating the first batch of data, the regulator said.

Rolling reviews allow drug companies to submit applications for COVID-19 medicinal products before development work is concluded and prior to the availability of complete supporting documentation, aimed at speeding up any approval process.

In October, Moderna had said it would apply for real-time reviews of its vaccine in Europe.

EMA's announcement comes a week after Switzerland began a real-time review of data from Moderna's vaccine candidate.

Moderna said earlier this month that it has enough data for a first interim analysis of its late-stage COVID-19 vaccine trial.